[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343967-105":59,"doc-detail-343967-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exceptional-sustained-long-term-complete-response-to-tepotinib-in-a-met-amplified-advanced-intrahepatic-biliary-tract-cancer-failing-durvalumab-plus-cisplatin-and-gemcitabine","Exceptional sustained long-term complete response to Tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine","","Biliary tract cancers remain difficult to treat, with limited options after first-line failure despite the use of checkpoint inhibitors and chemotherapy. This report describes a 25-year-old woman whose intrahepatic cholangiocarcinoma progressed on Durvalumab plus Cisplatin and Gemcitabine, with molecular profiling revealing TP53 mutation and MET amplification. Tepotinib initiation produced rapid tumor shrinkage and normalization of CA 19-9, achieving complete metabolic remission lasting up to 17 months. The treatment was well tolerated with minimal side effects, suggesting value for targeted second-line therapy in this rare molecular subgroup.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exceptional-sustained-long-term-complete-response-to-tepotinib-in-a-met-amplified-advanced-intrahepatic-biliary-tract-cancer-failing-durvalumab-plus-cisplatin-and-gemcitabine/343967/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exceptional-sustained-long-term-complete-response-to-tepotinib-in-a-met-amplified-advanced-intrahepatic-biliary-tract-cancer-failing-durvalumab-plus-cisplatin-and-gemcitabine/343967.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What led to choosing Tepotinib in this patient?","Question",{"text":112,"@type":113},"After progression on Durvalumab plus Cisplatin and Gemcitabine, molecular profiling identified MET amplification, and Tepotinib (a MET inhibitor) was started based on that targetable alteration.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How long did the patient’s complete response last?",{"text":117,"@type":113},"Tepotinib produced a complete metabolic remission that lasted up to 17 months on treatment.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is this case considered significant for MET-amplified biliary tract cancer?",{"text":121,"@type":113},"MET-amplified biliary tract cancers are exceedingly rare and targeted-treatment evidence is limited; this case demonstrates a durable, well-tolerated response to a molecularly informed therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343967,1790145594,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Exceptional sustained long-term complete response to Tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine  \nAndreas Reichinger1,3, Leo Essl3, Paul Kerschner3, Jonathan Burghofer2, Gerald Webersinke2, Holger Rumpold1,3, Bernhard Doleschal*, 1,3,  \n1Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz-Barmherzige Schwestern Site, Seilerstaette 4, 4020 Linz, Austria,  \n2Laboratory for Molecular Genetic Diagnostics, Ordensklinikum Linz-Barmherzige Schwestern Site, Seilerstaette 4, 4020 Linz, Austria, 3Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria  \n* Corresponding author: Bernhard Doleschal, Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz, Austria ([bernhard.doleschal@ordensklinikum.at](bernhard.doleschal@ordensklinikum.at)) .  \nAbstract  \nBackground: Biliary tract cancers (BTCs) are a diverse group of malignancies with varied genetic backgrounds. The prevalence of intrahepatic cholangiocarcinoma (iCC) is increasing, particularly in Western countries. Despite advancements in treatments, the prognosis for BTC remains poor. Recent molecular profiling has revealed that up to 40% of iCC cases have targetable genetic alterations. MET amplification, although rare, presents a significant target for therapy.  \nCase Presentation: A 25-year-old female with a history of ulcerative colitis presented with shoulder pain and a positron emission tomography–computed tomography (PET–CT) scan revealed an enlarged liver and multiple metastases. Histopathological analysis diagnosed poorly differentiated adenocarcinoma. First-line therapy with Cisplatin, Gemcitabine, and Durvalumab resulted in disease progression. Molecular profiling identified a TP53 mutation and MET amplification. Based on these findings, Tepotinib was initiated. Tepotinib treatment led to a significant reduction in tumor size and normalization of CA 19-9 levels within 2 months, achieving a complete metabolic remission lasting up to 17 months. The treatment was well tolerated with minimal side effects.  \nDiscussion: MET-amplified BTCs are exceedingly rare, and evidence for targeted treatment is limited. This case demonstrates the efficacy of Tepotinib in a young patient with MET-amplified iCC, showing a long-term response and suggesting a potential new standard treatment option for this molecularly defined entity. This case also highlights the aggressive nature of MET-amplified tumors and the need for targeted second-line therapies.  \nConclusion: Tepotinib showed remarkable efficacy in treating MET-amplified intrahepatic cholangiocarcinoma, underscoring the importance of molecular profiling in BTCs and suggesting a potential new therapeutic approach for this rare cancer subtype.  \nKey words: MET amplification; TP53 mutation; Tepotinib; biliary tract cancer; Durvalumab.  \nKey Points  \n• MET amplification, although rare in BTCs (2%-4%), is more commonly found in early-onset BTC.  \n• MET amplification drives aggressive tumor behavior and may contribute to resistance against the novel first-line standard of chemotherapy + checkpoint inhibitor, underscoring the need for targeted therapies in the second-line setting.  \n• Tepotinib is an effective and well-tolerated treatment for MET-amplified BTC, addressing a critical unmet need in managing this challenging and molecularly defined cancer subtype.  \nIntroduction  \nBiliary tract cancers (BTCs) represent a heterogeneous group of malignancies with varied anatomical distribution and genetic backgrounds.1 In Western countries, the prevalence  \nof intrahepatic cholangiocarcinoma (iCC) has been increasing, a trend attributed not only to lifestyle factors but also to advancements in diagnostic techniques.2 Despite recent progress in first-line treatments, such","cbCaiuPRrexuJjRO","https://ap.wps.com/l/cbCaiuPRrexuJjRO","pdf",12352805,"English","# Abstract\n## Background\n## Case Presentation\n## Discussion\n## Conclusion\n# Key Points\n# Introduction\n# Case Presentation","[{\"question\":\"What led to choosing Tepotinib in this patient?\",\"answer\":\"After progression on Durvalumab plus Cisplatin and Gemcitabine, molecular profiling identified MET amplification, and Tepotinib (a MET inhibitor) was started based on that targetable alteration.\"},{\"question\":\"How long did the patient’s complete response last?\",\"answer\":\"Tepotinib produced a complete metabolic remission that lasted up to 17 months on treatment.\"},{\"question\":\"Why is this case considered significant for MET-amplified biliary tract cancer?\",\"answer\":\"MET-amplified biliary tract cancers are exceedingly rare and targeted-treatment evidence is limited; this case demonstrates a durable, well-tolerated response to a molecularly informed therapy.\"}]","Exceptional sustained long-term complete response to Tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine | PDF",1790052639,13,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36e5e8e6f74569fb26629fe634342041.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55ed85d1544c746cec44bed6c0d39d5b.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f5677b3b1f107630da0616966d39b44.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a31d68db26fc5e8ceeb94bdc07d79af.webp",980,1287]